The Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) statistic previously introduced by Glasziou, Simes and Gelber (1990, Statistics in Medicine 9, 1259-1276) combines toxicity, disease-free survival, and overall survival information in assessing the impact of treatments on the lives of patients. This methodology has received positive reviews from clinicians as intuitive and useful, but to date, the variance of this statistic has remained unspecified. We review aspects of the Q-TWiST method for analyzing clinical trial data, extend the method to accommodate multiple treatment arms, and provide closed-form asymptotic variance formulas. We also provide a framework for designing Q-TWIST clinical trials with sample sizes determined using the derived asymptotic variance formulas. Trials currently collecting quality of life data did not have the benefit of these sample size calculation techniques in designing their studies.
Introduction
In making decisions about treatment effectiveness in clinical trials, several endpoints may be of interest. Many trials focus on overall survival (OS), but often simplifying the experiences of patients with this single endpoint is less than the whole story. For instance, in breast cancer clinical trials, it is interesting to compare the time a patient lives without recurrence of disease after initial treatment, or disease-free survival (DFS). Clinicians and patients are also interested in the duration of treatment-induced toxicity. The International Breast Cancer Study Group (IBCSG) Trial V collected data on all of these endpoints for the purpose of comparing nodepositive breast cancer patients randomized to receive as adjuvant treatments long-duration (6-7 months, N = 816) or short-duration (1 month, N = 413) chemotherapy (Ludwig Breast Cancer Study Group, 1988; Gelber et al., 1992a) . Inherent in collecting information on survival endpoints related to the end of toxicity, to recurrence, and to death is the notion that quality of life (QOL) varies in the stages demarked by these events. A complete picture of a patient's experiences on study cannot be established without considering each of these aspects simultaneously. In the IBCSG trial mentioned above, there was interest in evaluating gains in DFS and 0s
for the long-duration chemotherapy in light of its additional toxicity. Standard methods available for analyzing multiple endpoints are not designed to detect and resolve treatment differences that occur in different directions. Incorporating knowledge related to QOL in an analysis can be helpful in making treatment recommendations.
One avenue for exploring treatment effects has been proposed by Glasziou, Simes, and Gelber (1990) and is called Q-TWiST, or Quality-Adjusted Time Without Symptoms or Toxicity. The statistic was originally introduced as an extension to the Quality-Adjusted Life Year (QALY) method used in cost-effective analyses with uncensored endpoints, which attributes QOL weights between zero and one to distinct stages of a person's experience on study in producing an adjusted measure of survival time. However, in the nonparametric setting with bounded censoring, the unrestricted mean may not be identifiable. Using the same intuition of weighting the average time spent in each health state according a QOL measure between zero and one, Glasziou et al.'s Q-TWIST statistic allows for asymptotically unbiased estimation of the average QOL-adjusted survival time accumulated by some time, T , in the presence of censored endpoint data.
In Section 2, we describe and extend methods for Q-TWIST analysis of clinical trial data. To make inferences, suitable variance estimates of the Q-TWiST statistics are required. Currently, the bootstrap method has been employed without evidence that it is correctly estimating the variance. Section 3 0 2 -presents a closed-form asymptotic variance for the Q-TWIST statistic and recommended estimates. In deriving this asymptotic variance, we also derive the closed-form asymptotic covariance between dependent Kaplan-Meier (KM) estimates or between dependent Nelson-Aalen (NA) hazard estimates. Methods for estimating these dependent KM asymptotic COvariances without an exact closed form have been proposed by Wei and Lachin (1984) in relation to their nonparametric tests for equality of multivariate survival endpoints. Our more precise form for these covariances eases mathematical manipulation in Q-TWIST variance calculations required for this research. Additional precursor work characterizing the joint distribution of dependent survival endpoint random variables is well summarized by Anderson et al. (1993) . In particular, Prentice and Cai (1992) and Dabrowska (1988) describe nonparametric methods for estimating the joint distribution of two failure time endpoints.
Having a closed-form asymptotic variance improves our ability to make use of the Q-TWIST statistic in an inferential setting. In Section 4, we outline a strategy for determining sample sizes needed for detecting differences in QOL using the Q-TWIST statistic in clinical trials. Using the new Q-TWIST variance, an analysis is performed in Section 5 . A discussion follows in Section 6.
The Q-TWiST Methodology
The Q-TWIST approach to analyzing clinical trial data is appropriate in many disease settings. However, to simplify the presentation of methodology, we present Q-TWiST in the context of comparing adjuvant therapies for breast cancer, as in IBCSG Trial V. At the beginning of the study, the patients have already undergone surgery to remove all detectable cancer and are subsequently randomized to adjuvant therapies to attack remaining micro-metastatic cancer.
The first step in applying Q-TWiST is to define clinical endpoints that mark changes in a patient's QOL. Define TI as the duration of toxicity (TOX), which occurs from the beginning of the study until the end of treatment. Let Tz be time to disease relapse and T3 be time to death. Hence Tz -TI is the time without symptoms or toxicity (TWiST) that a patient experiences after chemotherapy and T3 -Tz is the time a person lives after disease recurrence (REL). Together, the three mutually exclusive states, TOX, TWiST, and REL, describe a patient's studytime experience. Although these endpoints are correlated, we assume they are not competing in nature. These methods should not be applied to multiple endpoints where observing one endpoint precludes the observation of another. Note that the methods described here generalize easily to circumstances where fewer or more health states are required to describe the course of disease.
For each treatment group, g, we estimate a QOL-adjusted
. . , 3 , and p~o x~ and ~R E L~ are weights between zero and one. The upper limit of integration, r , is chosen so that KM curves are consistent estimates for survival in the area of integration. Glasziou et al. (1990) suggest the median follow-up time as a reasonable choice. Other investigators may choose to maximize the region of area under the survival curve in choosing Area between survival curves corresponding to T , which would increase power to detect late-term differences in Q-TWIST. For notational convenience, we have restricted the upper limits of Qg to be the same, but the method extends to situations where the upper limits of integration differ.
The statistic, Qg, reflects the area under the 0s curve differentially weighted across mutually exclusive partitions corresponding to TOX, TWiST, and REL as depicted in Figure 1 with r = 2 years. The adjustment for QOL on each treatment arm in each survival state is incorporated through the weights p~o x~ and ~R E I ,~. If each weight equals one, Qs reduces to the unweighted area under the 0s curve and the analysis is based on survival time from study entry regardless of QOL. If each weight equals zero, Qy presents an analysis driven by length of TWiST so that no survival benefit is allowed for time patients spend in toxicity or in relapse. In most cases, weights are chosen to reflect some reduced benefit for life lived under treatment toxicity or relapse.
Various procedures for assigning the weights ~T O X~ and ~R E L~ a.re currently in practice or development. Several studies conducted by the IBCSG have begun collecting QOL information longitudinally from patients in order to estimate pT(iXg and /.LREI,~. However, QOL data is not routinely collected at this time, so many studies that could benefit from investigating QOL issues do not have data available to estimate weights. In this case, a sensitivity analysis may be done displaying results under various weighting scenarios. One advantage of this approach is that treatment recommendations can be tailored to individual QOL perceptions.
Let n = Cf=:=l ng and Q = (I$=:=, n g Q y ) / n , where ns is the number of patients on treatment g. Under the null hypothesis (Ho) of no treatment difference in this QOL-adjusted setting, Q = (Q1 -Q, Q2 -Q, . . . , QG-I -Q)' is asymptotically multivariate normal with mean vector 0 and variance-covariance C. A test statistic for comparing the G treatment groups is x2 = Q'C-lQ, which is asymptotically chi-squared with G-l d.f. The form of C will depend on whether fixed weights are used as part of a sensitivity analysis or whether the weights are estimated from data, in which case modification to accommodate the variation in the weights is required. This will be discussed further in Section 3, where a closed form for C is presented for both situations.
It is instructive to look at the special case with no censor- 3. Derivation of the Variance-Covariance Matrix, C, of the Quality-of-Life-Adjusted Q-TWiST Statistic In deriving a closed form for C , a closed-form asymptotic covariance between dependent KM survival estimates will be useful. Suppose we are interested in the covariance of KM estimators for two of the three dependent event times, Ti and T j , of the last section, with i, j E {1,2,3}. For each event time Ti, we define a censoring random variable Ui, a failure indicator Ai = I(Ti < U,), and observable event time
there is no restriction on the dependence between Ui and Uj or between T, and Tj for i # j . Often 171, U2, and Us will be exactly equal to one another. However, we allow a more general case where one endpoint, such as toxicity, is censored due to poor record keeping while other endpoint information is available.
In describing hazard functions used in the asymptotic covariances of KM estimates, &(z) and Sj(fv), we borrow terminology from Fleming and Harrington (1991) and Anderson et al. (1993) . We denote the usual marginal hazards at time u for Ti and Tj with Xi (. ) and X j ( u ) , respectively. Let the crude joint hazard X i j (u, u ) 
associated with time u for Ti has a risk set restricted to pa-
Since our primary interest in estimation relates to the marginal hazards of T, and T j , we do not need to make additional censoring assumptions relating the crude conditional and joint hazards to the usual net conditional and joint hazards for T, and Tj. For the purposes of describing the variance, accommodating such interpretations are unnecessary. An estimate for this covariance is also provided in Appendix A. As an additional check on our derivation, we have verified several familiar special cases. For instance, when X , and X , are independent, this covariance becomes zero. Also, when X , is identically equal to X,, this covariance reduces to the variance of the KM estimate. With uncensored data, where each KM estimate reduces to a simple proportion, (1) be- As expected, this result reduces to the case where weights are known when D~~~~ approaches zero. In cases where the weights are determined from a population-based average estimate, u w c 3 y / n~ is relatively small and the above can be simplified to = v; / n g , where 1
So the C, mth element of C from Section 2 in this case is
Recommended estimates for all variances from this section are located in Appendix B.
Study Design Considerations and
This section provides an example of how to calculate sample sizes for detecting differences in quality of life using the QTWiST statistic for two treatment group comparisons. We will discuss both the case where fixed weights are to be used and the case where population-based weights are estimated from patient data collected during the trial. In either case, the investigator should have input as to the number of health states patients experience, the projected survival behavior of endpoints defining these states, and the restriction time, T .
Let n be the desired sample size in each of two treatment groups being compared. Borrowing selected notation from
Simulation Results
previous sections, the test statistic using fixed wei hts may be represented as 2 = n1/2(Q1 -QZ)/(Vi + V2)lT2, which asymptotically behaves as a standard normal random variable. Note that if weights are estimated, we replace V1 and V2 with V : and V ; to account for extra variability. Under the alternative hypothesis, Q1 -Q2 has a nonzero mean, A , which measures the true difference in QOL-adjusted survival. Hence, 2 has asymptotic mean n1/2A/(V1 + V2)'/'. The distance between this alternative mean, n1/2A/(V1 + V2)lI2, and the zero mean, which holds true under Ho, can also be represented by z,p + zo, where a is the type I error chosen for the test, /3 is the type I1 error, and z* represents the percentile of the standard normal distribution that cuts off area * in the upper tail. Fkom this observation and some further algebra, we see that, for detecting the alternative A with power 1 -p and size a , the asymptotic relationship n = { (~, /~+ z o ) / A }~( V 1 +&) must be true or, specifically, in the fixed weights case, and in the estimated population-based weights case,
One may proceed determining sample sizes using these asymptotic formulas.
To demonstrate the use of these sample size formulas, we plan a QOL study where patients experience three different QOL states marked by survival endpoints, T l g , T2g, and T3g for the two treatment groups g = 1,2, where Tlg 5 Tzg 5
T3g. In each treatment group, the toxicity duration, Tlg, is taken to be independent of the length of time spent in the other two health states and is distributed as uniform(0,1/6). Hence, the simulated duration of toxicity corresponds to a duration incurred during a 2-month treatment course within each group.
Two sources of correlation between T2g and Tjg are incorporated into this simulation. The first source of correlation comes from the ordered nature of the survival endpoints, so larger observed T2g tend to result in larger observed values of Tsg. The second source of correlation comes from the relationship between Tig and T3gr the durations of time within the second and third health state, respectively, for those in group g . For instance, one might believe that a patient with large Tig will also tend to have larger Tig. To model the second source of correlation, we assume the distribution of the length of 
p 2 2 ) parameters are explored in order to study different levels of Q-TWiST treatment differences. Using these various parameters, the survival endpoints for each treatment group g become Tlg, Tzg = TlS + T;g and Tsg = T 2 g + T:*.
To model the censoring mechanism acting on the endpoints TIg, Tlg, and Tsgr we defined the random variable C = U x
I ( B = ~) + T x I ( B
= 0), where U is a uniform random variable on [1/6,7] and B is a Bernoulli random variable with success probability related to the desired level of censoring. Note that the percentage of censoring reported in Table 1 measures the degree of censoring in the study up to time 7 among each cohort of patients. All of the previously described survival and censoring distributions are used in simulation to estimate V 1 , V 2 , and A for 7 = 2 years in (2). Future programmers may decide to automate this procedure somewhat by querying the end user in relation to the marginal distributions for the endpoints and displaying results for a range of correlation parameters and censoring percentages. Since true values of V 1 and V 2 are not sample size-dependent, a sample size of 250 per treatment group is used to obtain estimates of V 1 and V 2 as described in Section 3 and then averaged over 5000 simulations of the data.
To estimate A, algebraic simplifications for A in the fully observed data case can be exploited since A is not affected by censoring levels. In this case, for any KM estimator S ( t ) on failure times t j with nT failures occurring prior to time 7, 10' S ( t ) d t = Ct, <T t J / n + 7 {I -(nT/n)}. For this simple calculation, it is possible to use a large sample size of 250,000 to estimate A. In order to make A even more precise, a Monte Carlo simulated average of A over 2500 simulations with this sample size was calculated. Using this method, A was accurate to roughly four decimal places. In Table I , estimated A's for Table 1 displays sample sizes required for 80% power and 5% type I error as determined from (2) or (3), as appropriate, under various censoring levels, (~1 2 , p 2 2 ) parameters, and weighting choices. Note that the sample sizes displayed assume a single statistical test. If multiple tests are used in a sensitivity analysis, the type I error may be adjusted according to the user's favorite method. Although this is an interesting and important topic, we will not devote any time discussing the issue of multiple comparisons, which is well documented elsewhere (e.g., Bickel and Doksum, 1977) . The four weighting choices displayed give a flavor for the different possible analyses using Q-TWIST. The first set of weights assigns p~o x = ~R E L = 0.5, which penalizes the TOX and REL states for reduced QOL in these time intervals. The second set of weights assigns ~T O X = ~R E L = 1, which reduces to a two-sample test comparing the restricted means for 0s.
The third displayed set of weights assigns ~T O X = ~R E L = 0 so that the analysis is driven by the time without symptoms or toxicity, completely discounting time spent in the TOX and REL health states in the analysis. The last column of sample sizes in Table 1 is based on the case where population-based weights are estimated from patient data. These estimated weights were simulated as normal random variables with mean 0.5 and variance 0.05/n in each treatment group, resulting in identical 8 ' s to the fixed weight case with ~T O X = ~R E L = 0.5 and largely similar estimated sample sizes. Figure 2 displays the survival endpoints for the smallest QTWiST treatment difference studied. Notice that the partitioned survival area corresponding to the TWiST health state is more favorable for the group with survival endpoints displayed on the left. Also, the area in the REL health state appears to be only slightly different in the two treatment groups.
One thousand Monte Carlo simulations were conducted to verify 80% power and 5% type I error planned for the analysis for selected entries of (79.4%, 77.7%, 80.5%) with corresponding type I error under Ho of (4.9%, 5.5%, 5.6%) in the fixed weights case and (79.6%, 77.5%, 80.3%) with corresponding type I error under Ho of (4.7%, 5.7%, 5.4%) in the estimated populationbased weights case. Empirical Q-TWiST variance estimates corresponding to these simulations matched closely with the simulation-specific Q-TWiST variance estimates. As an example, with 0% censoring with (piz, p22) = (-0.25, -0.25), the empirical variance across all simulations was 0.00245, whereas the (25%, 50%, 75%) quantiles for the observed Q-TWiST estimated variances using these formulas were (0.00243,0.00249, 0.00256). Under Ho, the empirical variance of 0.00248 compares favorably with the observed quantiles (0.00233, 0.00240, 0.00246). Results displayed in Table 1 and in further unreported simulations demonstrate that incorporating survival information related to the TOX and REL stat,es through partial weighting of these states in the Q-TWiST statistic increases the chances of detecting the simulated treatment differences. Interestingly, the statistic based on time spent in the TWiST state alone is almost as efficient as the statistic giving partial weights to the remaining states in this scenario. This happens primarily because the difference between partitioned areas under the survival curve for the two treatments occurs mainly within the TWiST health state for these selected distributions.
. Example
We now return to the IBCSG Trial V breast cancer study comparing long-versus short-duration chemotherapy mentioned in the introduction. Three health states were identified for the analysis: (1) time with toxicity due to chemotherapy (TOX), (2) time without toxicity or disease relapse (TWiST), and (3) time following disease relapse (REL). For the short-duration chemotherapy group, restricted mean estimates of TOX, DFS, and 0s within the 84-month median follow-up period were observed to be 0.85, 48.13, and 63.97 months with variances 0.00127, 2.35330, and 1.52404.
Covariance estimates of these restricted means were (ci21/413, V131/413, V231/413) = (0.00281,0.00137,1.46990).
In the long-duration group, TOX, DFS, and 0s 84-month restricted means were 5.79, 59.30, and 68.52 months with variances 0.00932, 1.04318, and 0.71836 and covariances (V1~2/8l6, c132/8l6, V2j2/816) = (0.00722,0.00254,0.74252).
Hence, the long-duration chemotherapy regimen has a longer duration of toxicity as well as increased DFS and 0s. A sensitivity analysis considering a large variety of weights provides the best perspective on overall treatment benefit when no QOL data is available for estimating the weights and also allows a clinical practitioner to assess potential treatment benefit profiles for patients with different perceived QOL. For a patient with high QOL in all disease stages, the usual analysis using ~T O X = ~R E L = 1 gives an average of 4.55 months of life gained on the long-duration chemotherapy in relation to the short-duration therapy during the first 84 months on study (95% CI: 1.616, 7.484). For a patient with little tolerance for toxicity, using ~T O X = ~R E L = 0, we find an average of 6.23 months of quality-adjusted life gained on the longduration chemotherapy in these 84 months (95% CI: 2.624, 9.836).
In Table 2 , we display mean estimated quality-adjusted survival differences between the long-and short-duration chemotherapies in months along with standard errors for a variety of weights considered by Gelber et al. (1991 Gelber et al. ( , 1995 . We also include bootstrap-based standard errors as used in their original analyses. In their papers, the weights ~T O X and ~R E L were assumed to be equivalent across treatment groups. Inferences using either the bootstrap or asymptotic closed-form variance estimates are similar. For most scenarios, the longduration chemotherapy provided a significantly longer QOLadjusted mean survival, even when adjusted for multiple comparisons. Cases where the sensitivity analysis did not distinguish a treatment preference involved weights that highly penalized toxicity while simultaneously judging near perfect QOL for the relapse health state. In the limited patient preference data available on these types of patients, these weight choices would not be typical. In fact, most patients rate the REL health state as inferior to the TOX health state in terms of QOL in these breast cancer studies. Hence, an analysis of this type would support assigning most patients to the longduration chemotherapy.
In this example, the bootstrap method provides estimates similar t o the closed-form-based estimates. Currently there is no research available to justify the appropriateness of bootstrapping covariances based on dependent marginal KM-based estimators such as we use in this research. In other work related to multiple failure-time endpoints, Yandell and Horvath (1988) demonstrated that the covariance of bivariate survival estimators can be successfully bootstrapped in cases where the true covariance is complex. This may turn out to be the case with dependent marginal survival estimates as well. " Long duration minus short duration (in months).
The bootstrap method used 1000 iterations in estimating variances who hold research positions in the Food and Drug Administration or the National Cancer Institute, pressed for statistical analyses of drug performance that incorporate multiple endpoints such as DFS, OS, and QOL in determining treatment recommendations. Already, the Q-TWIST technique has become a popular tool for this purpose. The basic methodology has been applied in a number of analyses of clinical trials. Gelber, Goldhirsch, and Cavalli (1991) and Gelber et al. (1992a) present analyses of adjuvant therapies for operable breast cancer, and Gelber et al. (1992b) and Lenderking et al. (1994) present analyses of zidovudine therapy for HIV infection. Cole et al. (1996) evaluated the risks and benefits of high-dose interferon alfa-2b adjuvant treatment for malignant melanoma. Gelber et al. (1996) evaluated chemotherapy plus radiation therapy for rectal cancer. In addition, a number of methodological extensions to Q-TWIST have been proposed. Incorporation of covariates and prognostic factors in a Q-TWIST analysis have been proposed by Cole, Gelber, and Goldhirsch (1993) using proportional hazards models and by Cole, Gelber, and Anderson (1994) using accelerated failure time models. An overview of recent extensions is given by Gelber et al. (1995) . In a related recent extension of the original Q-TWiST methodology, Zhao and Tsiatis (1997) discuss a consistent estimator for the distribution, a s opposed to the mean, of a lifetime adjusted for known QOL weights along with a consistent variance estimate without requiring a progression of health states as in the original paper by Glasziou, Simes, and Gelber (1990) or this work. Their distribution relates to the distribution of the Q-TWIST statistic in the case where the known weights are piecewise constant. An advantage to the variance calculations based on partitioned survival as in this work is that this approach can easily accommodate estimated weights, while the estimator of Zhao and Tsiatis remains valid only with known weights. Since estimated weights are critical when studying patients' perceived QOL, this is an important distinction.
This research expands the methodological framework of the Q-TWIST procedures by providing closed-form variances of the treatment-specific QOL-adjusted survival estimates and test statistics. Simulations using the newly derived variance show that, in addition to a more complete assessment of a treatment's performance, we may in fact increase our power to detect clinical differences when QOL considerations are included in an analysis. In addition, this research outlines an example of how to design a clinical trial with appropriate sample sizes to detect clinical differences using the Q-TWiST method. Currently the clinical trials collecting QOL information have not had the benefit of these strategies for assuring an adequately powered study.
Hence, determining the asymptotic behavior of dependent NA estimates will provide us with an understanding of the asymptotic behavior for dependent KM estimates. For each of the dependent event times of interest, i = 1,2, define Uzk as the censoring random variable corresponding to T i k , Also define N i ( t ) = CE=, I ( X i k 5 t , A i k = 1) and Yi(t) = c;=, I ( x i l , 2 t ) . Let M i ( t ) = N i ( t ) -1; Xi(u)yZ(u) du be the martingale defined with respect to the filtration containing all available censoring and survival data for the endpoint corresponding to i prior to time t and define M j ( t ) = N,(t) -1; Xj(u) YJ (u)du similarly for endpoint type j . The filtrations concerning Mi (t) and MJ ( t ) are dependent but not necessarily nested. Hence, we explicitly derive covariances relating to these martingales without using the usual strategy of conditioning on a common filtration. In terms of the NA estimator, we need to find the covariance of terms taking the form Since, according to the Glivenko and Cantelli theorem, we rewrite the above as which after an application of the martingale central limit theorem (or Lenglart's Inequality) has the same limiting distri- = s"J" A,, (u, v) 0 0
